Abstract
Background:
The gene COQ2, encoding 4-hydroxybenzoate-polyprenyltransferase (coenzyme Q2), belongs to the candidates potentially influencing statin treatment tolerability. This enzyme is involved in the biosynthesis of coenzyme Q10 (CoQ10), in which depletion induced by statin treatment is implicated in the development of statin-associated muscle symptoms (SAMS). Thus, polymorphisms in the COQ2 gene might explain susceptibility to SAMS.
Methods:
Adult patients with SAMS (on low doses of atorvastatin and simvastatin)-induced myalgia/myopathy (n=278), patients on statins but without SAMS (n=293) and population (part of the post-MONICA [Multinational MONItoring of trends and determinants in CArdiovascular disease] study) controls (n=561) were genotyped (polymerase chain reaction-restriction fragment length polymorphism [PCR-RFLP] assay) for rs6535454 and rs4693075 polymorphisms within the COQ2 gene loci.
Results:
Distribution of rs6535454 in patients with SAMS (GG=51.1%, GA=40.0%, AA=8.9%) did not significantly differ (p=0.33; respectively 0.32 for codominant models of the analysis) from that in the population controls (GG=48.1%, GA=45.0%, AA=6.9%) or the SAMS-unaffected patients (GG=49.8%, GA=40.3%, AA=9.7%). Similarly, neither rs4693075 was associated with SAMS (CC=36.8%, CG=48.2%, GG=15.0% in patients suffering SAMS vs. CC=36.6%, CG=47.5%, GG=15.9 in controls and CC=35.8%, CG=48.2%, GG=15.9% in symptom-free patients, p=0.94 and 0.95 for codominant models of the analysis). Also, the haplotype distributions were not significantly different between the groups analyzed.
Conclusions:
The polymorphisms of the COQ2 gene do not associate with SAMS in the Czech patients treated with low doses of statins. This is another clue that the coenzyme Q10 pathway is not the most important for the development of SAMS.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Supported by the Ministry of Health Czech Republic – conceptual development of research organisation (“Institute for Clinical and Experimental Medicine – IKEM, IN 00023001”).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Tamosiunas A, Luksiene D, Baceviciene M, Bernotiene G, Radisauskas R, Malinauskiene V, et al. Health factors and risk of all-cause, cardiovascular, and coronary heart disease mortality: findings from the MONICA and HAPIEE studies in Lithuania. PLoS One 2014;9:e114283.10.1371/journal.pone.0114283Search in Google Scholar PubMed PubMed Central
2. Petursson H, Sigurdsson JA, Bengtsson C, Nilsen TI, Getz L. Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study. J Eval Clin Pract 2012;18:927–8.10.1111/j.1365-2753.2012.01863.xSearch in Google Scholar PubMed
3. Hubáček JA. High cholesterol is not associated with increased mortality. [Article in Czech] Hyper Kardiovask Prevence 2015;3:58–62.Search in Google Scholar
4. Hubacek JA, Stanek V, Gebauerova M, Adamkova V, Lesauskaite V, Zaliaduonyte-Peksiene D, et al. Traditional risk factors of acute coronary syndrome in four different male populations – total cholesterol value does not seem to be relevant risk factor. Physiol Res 2017;66(Suppl 1):S121–28.10.33549/physiolres.933597Search in Google Scholar PubMed
5. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;270:65–75.10.1111/j.1365-2796.2010.02333.xSearch in Google Scholar PubMed
6. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. J Am Med Assoc 2016;316:2008–24.10.1001/jama.2015.15629Search in Google Scholar PubMed
7. Endo A. Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors. Klin Wochenschr 1988;66:421–7.10.1007/BF01745510Search in Google Scholar PubMed
8. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004;93:31–9.10.1016/j.amjcard.2003.09.008Search in Google Scholar PubMed
9. Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res 2014;63(Suppl 3):S327–34.10.33549/physiolres.932865Search in Google Scholar PubMed
10. Fernandes V, Santos MJ, Pérez A. Statin-related myotoxicity. Endocrinol Nutr 2016;63:239–49.10.1016/j.endonu.2016.01.001Search in Google Scholar PubMed
11. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005;19:403–14.10.1007/s10557-005-5686-zSearch in Google Scholar PubMed
12. Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr 2013;5:1.10.1371/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203Search in Google Scholar PubMed PubMed Central
13. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4–15.10.1016/j.nmd.2013.09.011Search in Google Scholar PubMed
14. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis 2007;6:7.10.1186/1476-511X-6-7Search in Google Scholar PubMed PubMed Central
15. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28–9.10.1016/j.atherosclerosis.2010.02.026Search in Google Scholar PubMed
16. Ruaño G, Windemuth A, Wu AH, Kane JP, Malloy MJ, Pullinger CR, et al. Mechanisms of statin induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011;218:451–6.10.1016/j.atherosclerosis.2011.07.007Search in Google Scholar PubMed PubMed Central
17. Hubacek JA, Adamkova V, Lanska V, Dlouha D, Rynekrova J, Zlatohlavek L, et al. Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. J Appl Biomed 2012;10:19–28.10.2478/v10136-012-0001-3Search in Google Scholar
18. Hubacek JA, Adamkova V, Hruba P, Ceska R, Vrablik M. Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. Eur J Intern Med 2015;26:367–8.10.1016/j.ejim.2015.02.019Search in Google Scholar PubMed
19. Hubacek JA, Dlouha D, Adamkova V, Zlatohlavek L, Viklicky O, Hruba P, et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit 2015;21:1454–9.10.12659/MSM.893007Search in Google Scholar PubMed PubMed Central
20. Vrablík M, Hubáček JA, Dlouhá D, Lanska V, Rynekrova J, Zlatohlavek L, et al. Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res 2012;61:609–17.10.33549/physiolres.932341Search in Google Scholar PubMed
21. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1–23.10.5114/aoms.2015.49807Search in Google Scholar PubMed PubMed Central
22. Cífková R, Skodová Z, Bruthans J, Adámková V, Jozífová M, Galovcová M, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010;211:676–81.10.1016/j.atherosclerosis.2010.04.007Search in Google Scholar PubMed
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for DNA extraction from human nucleated cells. Nucleic Acid Res 1988;16:1215.10.1093/nar/16.3.1215Search in Google Scholar
24. Gluba-Brzozka A, Franczyk B, Toth PP, Rysz J, Banach M. Molecular mechanisms of statin intolerance. Arch Med Sci 2016;12:645–58.10.5114/aoms.2016.59938Search in Google Scholar PubMed
25. Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol 2017;70:1290–301.10.1016/j.jacc.2017.07.752Search in Google Scholar PubMed
26. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351–61.10.1016/S0140-6736(14)61183-1Search in Google Scholar PubMed
27. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, et al. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid lowering response to statin in Greek patients with primary hypercholesterolemia. Drug Metab Pers Ther 2015;30:43–8.10.1515/dmdi-2014-0021Search in Google Scholar PubMed
28. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011;21:280–8.10.1097/FPC.0b013e328343dd7dSearch in Google Scholar PubMed PubMed Central
29. Voora D, Shah SH, Spasovejic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin induced side effects. J Am Coll Cardiol 2009;54:1609–16.10.1016/j.jacc.2009.04.053Search in Google Scholar PubMed PubMed Central
30. Alfonsi JE, Hegele RA, Gryn SE. Pharmacogenetics of lipid-lowering agents: precision or indecision medicine? Curr Atheroscler Rep 2016;18:24.10.1007/s11883-016-0573-6Search in Google Scholar PubMed
31. Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol 2017;83:1176–84.10.1111/bcp.13207Search in Google Scholar PubMed PubMed Central
32. Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol 2011;5:91–6.10.1016/j.jacl.2011.01.001Search in Google Scholar PubMed
33. Neroldova M, Stranecky V, Hodanova K, Hartmannova H, Piherova L, Pristoupilova A, et al. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy. Pharmacogenomics 2016;17:1405–14.10.2217/pgs-2016-0071Search in Google Scholar PubMed
34. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004;61:889–92.10.1001/archneur.61.6.889Search in Google Scholar PubMed
35. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012;110:526–9.10.1016/j.amjcard.2012.04.026Search in Google Scholar PubMed
36. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015;238:329–35.10.1016/j.atherosclerosis.2014.12.016Search in Google Scholar PubMed PubMed Central
37. Zlatohlavek L, Vrablik M, Grauova B, Motykova E, Ceska R. The effect of coenzyme Q10 in statin myopathy. Neuro Endocrinol Lett 2012;33(Suppl 2):98–101.Search in Google Scholar PubMed
38. Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015;90:24–34.10.1016/j.mayocp.2014.08.021Search in Google Scholar PubMed
39. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373–418.10.2165/0129784-200808060-00004Search in Google Scholar PubMed PubMed Central
40. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231–7.10.1016/j.jacc.2007.02.049Search in Google Scholar PubMed
41. Carr DF, O‘Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 2013;94:695–701.10.1038/clpt.2013.161Search in Google Scholar PubMed PubMed Central
42. Hopewell JC, Reith C, Armitage J. Pharmacogenomics of statin therapy: any new insights in efficacy or safety? Curr Opin Lipidol 2014;25:438–45.10.1097/MOL.0000000000000125Search in Google Scholar PubMed
43. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94–102.10.1002/path.2018Search in Google Scholar PubMed
44. Apellaniz-Ruiz M, Gallego C, Ruiz-Pinto S, Carracedo A, Rodríguez-Antona C. Humen genetics: international projects and personalised medicine. Drug Metab Pers Ther 2016;31:3–8.Search in Google Scholar
45. Maroñas O, Latorre A, Dopazo J, Pirmohamed M, Rodríguez-Antona C, Siest G, et al. Progress in pharmacogenetics: consortiums and new strategies. Drug Metab Pers Ther 2016;31:47–54.10.1515/dmpt-2015-0039Search in Google Scholar PubMed
46. García-González X, Cabaleiro T, Herrero MJ, McLeod H, López-Fernández LA. Clinical implementation of pharmacogenetics. Drug Metab Pers Ther 2016;31:9–16.10.1515/dmpt-2015-0031Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
